ZE94-0605
/ Eilean Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 16, 2025
Eilean Therapeutics…announced the presentation of preclinical data for its novel, brain-permeable CDK2 inhibitor at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(PRNewswire)
- "The compound demonstrates high selectivity for CDK2 over other cyclin-dependent kinases (CDKs), excellent safety and tolerability, and a broad therapeutic window in models of multiple cyclin-E1 (CCNE1)–CDK2–dependent neoplasms....Eilean plans to...advance this highly selective CDK2 inhibitor into a First-in-Human clinical study in Q4 2025."
New trial • Preclinical • Oncology
1 to 1
Of
1
Go to page
1